

AL Amyloidosis Market Set for Strong Growth by 2034, Predicts DelveInsight

DelveInsight's report on AL Amyloidosis provides a comprehensive analysis of the epidemiology and market trends across the 7MM.

LAS VEGAS , NV, UNITED STATES, January 24, 2025 /EINPresswire.com/ -- DelveInsight's "AL Amyloidosis Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of the AL Amyloidosis, historical and forecasted epidemiology as well as the AL Amyloidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

To Know in detail about the AL Amyloidosis market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: [AL Amyloidosis Market Forecast](#)

Some of the key facts of the AL Amyloidosis Market Report:

- The AL Amyloidosis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
- AL Amyloidosis is a rare and serious disease, with an estimated 8,600 incident cases in the 7MM countries (United States, EU5—Germany, France, Italy, Spain, and the United Kingdom—and Japan) in 2021.
- The AL Amyloidosis market size across the 7MM was approximately USD 920 million in 2021.
- In January 2025, Life Molecular Imaging (LMI) announced that the U.S. FDA granted Fast Track Designation to [18F]florbetaben for the diagnosis of cardiac amyloid light-chain (AL) and amyloid transthyretin-related (ATTR) amyloidosis. Florbetaben had previously received orphan drug status in both the EU and the US for the management of AL amyloidosis.
- Emerging therapies for AL Amyloidosis include Daratumumab, Birtamimab, CAEL-101, Melflufen, Elotuzumab, and others.
- Leading companies in the AL Amyloidosis market include Janssen Pharmaceutical, Prothena, Alexion Pharmaceuticals, Oncopeptides AB, Bristol-Myers Squibb, and others.
- The AL Amyloidosis market is expected to experience substantial growth, driven by the rising demand for effective therapies, advances in genetic research, and ongoing clinical trials focused on improving patient outcomes for this rare neurodegenerative disease.

AL Amyloidosis Overview

AL (light chain) amyloidosis is a rare and serious condition caused by the deposition of misfolded

immunoglobulin light chains produced by abnormal plasma cells. These light chains form amyloid fibrils that accumulate in various organs, leading to organ dysfunction, with the heart, kidneys, nerves, and liver most commonly affected. Symptoms can include heart failure, kidney failure, peripheral neuropathy, and fatigue. Treatment focuses on addressing the underlying plasma cell disorder through chemotherapy, stem cell transplantation, or monoclonal antibodies to reduce amyloid production and prevent further organ damage.

Get a Free sample for the AL Amyloidosis Market Report:

https://www.delveinsight.com/report-store/al-amyloidosis-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=jpr

AL Amyloidosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

AL Amyloidosis Epidemiology Segmentation:

The AL Amyloidosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

- AL Amyloidosis Incident cases
- AL Amyloidosis Gender-Specific Cases
- AL Amyloidosis Age-specific Cases

Download the report to understand which factors are driving AL Amyloidosis epidemiology trends @ [AL Amyloidosis Epidemiology Forecast](#)

AL Amyloidosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the AL Amyloidosis market or expected to be launched during the study period. The analysis covers the uptake of drugs in the AL Amyloidosis market, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the AL Amyloidosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

AL Amyloidosis Therapies and Key Companies

- Daratumumab: Janssen Pharmaceutical
- Birtamimab: Prothena
- CAEL-101: Alexion Pharmaceuticals
- Melflufen: Oncopeptides AB
- Elotuzumab: Bristol-Myers Squibb

AL Amyloidosis Market Strengths

- Increasing recognition of AL Amyloidosis by healthcare professionals, along with advancements in diagnostic tools like [18F]florbetaben, is leading to more accurate and timely diagnoses, driving market growth.
- The development of novel therapies, such as Daratumumab and Birtamimab, provides new treatment options, improving outcomes for patients and fueling market expansion.

AL Amyloidosis Market Opportunities

- Despite recent progress, there is a significant unmet need for more effective and targeted treatments for AL Amyloidosis, creating opportunities for innovative therapies to enter the market.
- With increasing awareness and advancements in healthcare infrastructure, expanding treatment access in emerging markets presents a significant growth opportunity for AL Amyloidosis therapies.

Scope of the AL Amyloidosis Market Report

- Study Period: 2020–2034
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key AL Amyloidosis Companies: Janssen Pharmaceutical, Prothena, Alexion Pharmaceuticals, Oncopeptides AB, Bristol-Myers Squibb, and others.
- Key AL Amyloidosis Therapies: Daratumumab, Birtamimab, CAEL-101, Melflufen, Elotuzumab, and others.
- AL Amyloidosis Therapeutic Assessment: AL Amyloidosis current marketed, and AL Amyloidosis emerging therapies
- AL Amyloidosis Market Dynamics: AL Amyloidosis market drivers and AL Amyloidosis market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- AL Amyloidosis Unmet Needs, KOL's views, Analyst's views, AL Amyloidosis Market Access and Reimbursement

To learn more about AL Amyloidosis companies working in the treatment market, visit @ [AL Amyloidosis Clinical Trials and Therapeutic Assessment](#)

Table of Contents

1. AL Amyloidosis Market Report Introduction
2. Executive Summary for AL Amyloidosis

3. SWOT analysis of AL Amyloidosis
4. AL Amyloidosis Patient Share (%) Overview at a Glance
5. AL Amyloidosis Market Overview at a Glance
6. AL Amyloidosis Disease Background and Overview
7. AL Amyloidosis Epidemiology and Patient Population
8. Country-Specific Patient Population of AL Amyloidosis
9. AL Amyloidosis Current Treatment and Medical Practices
10. AL Amyloidosis Unmet Needs
11. AL Amyloidosis Emerging Therapies
12. AL Amyloidosis Market Outlook
13. Country-Wise AL Amyloidosis Market Analysis (2020–2034)
14. AL Amyloidosis Market Access and Reimbursement of Therapies
15. AL Amyloidosis Market Drivers
16. AL Amyloidosis Market Barriers
17. AL Amyloidosis Appendix
18. AL Amyloidosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Jatin Vimal

DelveInsight Business Research LLP

+1 469-945-7679

info@delveinsight.com

This press release can be viewed online at: <https://www.einpresswire.com/article/779954523>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.